GSK and Ochre Bio will work together in a $37.5 million partnership to pinpoint the drivers of liver disease.

The new partnership, announced Wednesday morning, will see GSK access Ochre’s computational biology, cellular and perfused human organ platforms to generate human liver data sets that can be used to better understand the biology of the liver.

Boehringer Ingelheim is making yet another bet that RNA therapies hold the key to treating metabolic-associated steatohepatitis (MASH).

The German drugmaker is paying British biotech Ochre Bio $35 million in upfront and near-term research-based milestone payments to investigate “multiple targets” for chronic liver disease. Top of the list of indications will be MASH, previously known as nonalcoholic steatohepatitis (NASH).

Proceeds to support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases.